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Summanr The clonogenic growth inhibition. the cell cycle dependence of N4-hexadecyv-I-P-E-
arabinofuranosylcytosine (NHAC) cytotoxicity and the capability to induce apoptosis in ara-C-sensitive and
-resistant HL-60 cells were investigated and compared with arabinofuranosvlcytosine (ara-C). In the
clonogenic assay with sensitive HL-60 cells. ara-C was slightly more effective than a liposomal preparation of
NHAC. whereas in the resistant cells. NHAC revealed its potency to overcome ara-C resistance, resulting in a
23-fold lower 5000 inhibitory concentration compared with ara-C. Cell cycle dependent cytotoxicity and
induction of apoptosis were studied by flow cytometry, using the bromodeoxyuridine-propidium iodide and
terminal transferase method respectively- In contrast to ara-C. NHAC exerted no phase-specific toxicity at low
concentrations ( <40AM). At higher concentrations the S-phase-specific toxicity increased. probably resulting
from ara-C formed from NHAC_ NHAC induced apoptosis at higher drug concentrations than ara-C.
however apoptosis appeared not to be limited to the S-phase cells. Apoptosis occurred in both cell lines within
2-4 h after drug exposure. These results give further evidence that NHAC exerts its cytotoxicity by different
mechanisms of action than ara-C and might therefore be active in ara-C-resistant tumours.
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Apoptosis is a genetically programmed. active cell death that
plays an essential role in the control of normal tissue and
tumour cells (Wyllie et al.. 1980). Cells undergoing apoptosis
show a series of typical morphological changes such as
chromatin condensation. cell shrinkage, DNA degradation
and packaging of cell remnants into apoptotic bodies
(Cohen. 1993). The characteristic event of apoptosis is the
activation of an endonuclease with preference to the inter-
nucleosomal linker DNA sections. resulting in DNA
fragments of multiples of 180-200 bp in size (Arends et al.,
1990). By agarose gel electrophoresis these DNA fragments
are displayed in a typical ladder pattern (Kaufmann, 1989).
However, morphologically identified apoptosis is not always
accompanied by internucleosomal DNA fragmentation
(Cohen et al., 1992).
The efficacy of different anti-tumour drugs has been
associated with their ability to induce apoptosis. Thus.
different topoisomerase I or II inhibitors and a variety of
diverse cytotoxic agents such as methotrexate, cis-platinum
or l-P-D-arabinofuranosylcytosine (ara-C) have been demon-
strated to induce endonucleolytic DNA cleavage (Kaufmann,
1989; Gorczyca et al., 1993a). Although the initiating key
element for inducing this cascade leading to cell death is not
yet known, it has been shown by different investigators (Fiet-
kau et al.. 1984: Cavazzana et al., 1988) that cells progressing
through the S-phase were selectively susceptible to induction
of apoptosis when treated with ara-C. The cell cycle-
dependent cytotoxicity of ara-C is caused by the inhibition of
DNA synthesis and DNA polymerase activity followed by
incorporation of ara-CTP into DNA. causing a block of GI
cells at the GI S border. Thus, ara-C is not very efficient in
the killing of GI cells (Karon and Shirakawa, 1969).
M-hexadecyl-l-P-D-arabinofuranosylcytosine (NHAC) is a
new lipophilic derivative of ara-C, one of the most widely
used agents for the treatment of acute myelogenous
leukaemia. In previous studies, NHAC was shown to exert
stronger anti-tumour activity than ara-C in the L1210 mouse
leukaemia even at single dose schedules (Schwendener and
Schott. 1992; Schwendener et al.. 1995). Studies about the
cellular pharmacologp of NHAC in HL-60. K-562 and U-937
cells resulted in an intracellular half-life, which was up to five
times longer than that of ara-C (Horber et al., 1995a,b).
Owing to its lipophilicity, NHAC is predominantly dist-
ributed in the cellular membranes. After intravenous
administration NHAC is rapidly released from the liposome
membranes and transferred to plasma proteins and erythro-
cytes (Horber et al., 1995c). In spite of the finding that small
amounts of ara-C are formed from NHAC by metabolic
processes, we suggested that NHAC is not only a prodrug of
ara-C (Horber et al., 1995a). Thus. NHAC is still cytotoxic
in ara-C-resistant HL-60 cells. In other experiments the
cytotoxicity of NHAC was shown to be largely independent
of the phosphorylation pathway as demonstrated by co-
incubations with the competitive ara-C phosphorylation
inhibitor 2'-deoxycytidine. These results gave evidence that
NHAC might be active by yet unknown mechanisms of
action. To further elucidate these findings, we studied in the
present work the cytotoxicity of NHAC in a clonogenic
assay, the cell cycle dependence of the NIHAC cytotoxicity as
well as the induction of apoptosis by NHAC in HL-60 and
HL-60,,ara-C-resistant cells.
Material and methods
Drugs
Ara-C, 5-bromo-2'-deoxyuridine (BrdUrd). Tween 20, bovine
serum albumin (BSA), propidium iodide (PI). cacodylic acid,
fluoresceinated avidin and RNAse A were purchased from
Sigma Chemical (Buchs, Switzerland). Terminal transferase
(TdT) and biotin-16-2'-deoxy-uridine-5'-triphosphate (b-
dUTP) were purchased from Boehringer Mannheim (Rot-
kreuz, Switzerland). RPMI-1640 medium, minimal essential
medium (MEM), Hanks' balanced salt solution (HBSS) and
agar gel 2% were purchased from Gibco (Paisley, UK). For
all incubations, ara-C was dissolved in phosphate-buffered
saline PBS (8 mM sodium phosphate 1.5 mM potassium
dihydrogen phosphate, 0.14 M sodium chloride, 2.6 mM
potassium chlonrde). NHAC was given in a liposomal for-
mulation as described in the Liposome preparation section.
NHAC was synthesised as previously described (Schwendener
and Schott, 1992).
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Cells
HL-60 promyelocytic leukaemia cells were obtained from the
Amenrcan Type Tissue Culture Collection (ATCC CCL 240).
The ara-C-resistant HL-60 cells (HL-60/ara-C) were a kind
gift from Dr Studzinski, UMD-New Jersey Medical School,
Newark, NJ, USA (Kolla and Studzinski, 1994). This HL-60/
ara-C subline has been isolated and characterised by Bhalla
et al. (1984). The cells were grown in RPMI-1640 medium
supplemented with 10% heat-inactivated fetal calf serum
(FCS; PAA-Biologics, Linz, Austria), 100 units ml-' penicil-
lin and 100jig ml' streptomycin in a humidified 5% carbon
dioxide atmosphere. The experiments were initiated in
logarithmically growing cultures at a density of 3-5 x 10I
cells mn '.
Liposome preparation
Small unilamellar liposomes of 100 ± 30 nm mean diameter
were prepared by filter extrusion as described by Hope et al.
(1985). Briefly, lipid mixtures composed of soy phosphatidyl-
choline (SPC), cholesterol, D,L-<-tocopherol and NHAC at a
molar ratio of 1:0.2:0.01:0.1 were hydrated with PBS and
sequentially filtrated through Nuclepore (Costar, Sterico,
Dietikon, Switzerland) filters of decreasing pore size (1 ILm,
400 nm, 100 nm). Liposomes without NHAC, termed empty
liposomes, were used as control. All preparations (20 mg SPC
ml-') were sterilised by filtration through 0.2 ;m filters
(Acrodisc, Gelman Sciences, Ann Arbor, MI, USA) and
stored at 4°C.
Clonogenic assav
Cells (2 x 10 cells per well) were exposed to various concen-
trations (0-400gM) of ara-C, NHAC or empty liposomes for
24 h at 37°C (5% carbon dioxide). After washing twice with
PBS, the cells (5 x I04 cells per well) were plated in 2 ml
MEM containing 20% FCS and 0.3% agar. Cultures were
incubated for 14-21 days at 37°C (5% carbon dioxide).
Colonies (. 50 cells) were scored using an inverted micro-
scope at a 30 x magnification. Plating efficiency was 1.3% for
HL-60 and 3.6% for HL-60/ara-C cells. All experiments were
repeated four times.
Cell cycle distribution analysis
Cells (2 x 106 cells per well) were exposed to various concen-
trations (0-400gM) of ara-C, NHAC or empty liposomes for
24 h at 37°C (5% carbon dioxide) or for various time periods
(0-8 h) with 50 gM ara-C or NHAC. After washing once in
RPMI-1640 medium, the cells were incubated with lOjiM
BrdUrd for 30 min at 37°C. After centrifugation, the cells
were washed once in cold HBSS and resuspended in 500 tlA of
HBSS. Cells were then injected through a fine needle into
4.5 ml of 80% ethanol (precooled to - 20C) for fixation and
stored at - 20'C for up to 3 days. The BrdUrd/PI staining
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Fge 1 Clonogenic assays in HL-60 (a) and HL-60/ara-C-
resistant cells (b). Cells were incubated with ara-C (M), NHAC-
liposomes (0) or empty liposomes (x) for 24 h at 3TC (5%
carbon dioxide) at a concentration range from 0.1 -400 gM.
Clonogenic growth was scored 14-21 days after plating 50000
cells per well in MEM containing 0.3% agar. Symbols are mean
of four separate experiments; bars = s.d.
Table I Cell cycle distribution in HL-60 and HL-60/ara-C cells after incubation with ara-C
or NHAC for 24 h at increasing drug concentrations'
Drug Distribution in HL-60 cells (%) Distribution in HL-60,lara-C (%)
(AL}) GI S Sob G2M GI s Sob G2,M
Ara-C
0 59.3c 32.7 0.3 7.7 27.9 56.2 1.5 13.8
1 69.4 4.4 10.9 15.3 25.3 60.3 1.5 12.8
10 72.1 3.3 9.9 14.7 27.9 64.0 1.0 7.1
40 74.4 3.2 8.5 13.9 22.5 65.3 1.9 10.3
100 73.5 3.3 9.4 13.9 27.9 60.8 4.8 6.5
200 69.9 3.4 10.6 16.1 42.5 35.5 11.1 10.9
400 65.5 3.4 13.9 20.2 53.5 16.5 16.1 13.8
NHAC
0 50.8 34.7 0.8 13.7 27.3 56.1 0.6 16.0
1 52.2 36.4 1.0 10.4 27.9 57.2 0.7 14.2
10 53.6 37.0 1.7 7.7 28.5 56.1 0.6 14.8
40 56.8 31.1 3.3 8.8 33.0 53.5 0.8 12.7
100 67.5 13.0 9.9 9.6 35.6 51.9 0.8 11.7
200 67.4 8.7 14.4 9.5 48.2 39.3 2.0 10.5
400 64.1 8.3 16.1 11.5 55.1 31.8 2.5 10.7
'Cell cycle distribution determined using the BrdUrd-PI method. b'S cell fraction as
described in the text. cMean of cell cycle fractions (%) of two separate experiments. s.d. was
<100% of mean value.
1068was performed with minor modifications as described by
Lacombe et al. (1988). Briefly, after centrifugation. the cells
were treated with 2 N hydrochloric acid for 30 min at 20C
and then washed three times with PBS + 0.5% Tween 20.
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Figure 2 Cell cycle distnrbution of untreated HL-60 cells (a) or
cells after treatment with 40 iLM ara-C (b) or NHAC (c) for 24 h
at 37C (5% carbon dioxide) by flow cytometry analysis. After
incubation the ceUls were pulse labeUled with 10 M BrdUrd for
30 min. Staining was performed after cell fixation using PI- and
FITC-labelled MAb against BrdUrd. Data are shown as contour
plots with DNA content on the x-axis (FL-2, red fluorescence)
and BrdUrd content on the y-axis (FL-1, green fluorescence). GI,
S and GJM phase distnrbution was quantified by gating the cell
population. All experiments were performed in duplicate.
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The cells were resuspended in 501l of PBS + 0.50% Tween
20 + 1% BSA and reacted with 10 il of FITC-labelled
monoclonal anti-BrdUrd antibody (MAb, Becton-Dickinson,
San Jose, CA, USA) for 30 mn at 20C. Then 1 ml of
PBS +PI (1O iLg ml-) was added and the samples stored at
4°C for 1 h.
DNA gel electrophoresis
Cells (2 x 106 cells per well) were exposed for various time
periods (0-8 h) with 50 giM ara-C or NHAC at 37TC (500
carbon dioxide). DNA extraction was carried out with minor
modifications as described by Kaufmann (1989). Briefly, the
cells were washed once with PBS and lysed in 300gil lysis
buffer (0.5 M Tris-HCI pH 9.0. 2 mM EDTA. 10 mM sodium
chloride. 1% sodium dodecyl sulphate (SDS). 0.33 mg ml-'
proteinase K). The samples were incubated at 50°C for 24 h.
extracted twice with phenol chloroform (1:1. v v) and once
with chloroform. The probes were then incubated with
300gg ml - RNAse A and loaded onto 1.2% (w v) agarose
gels. DNA from 2 x I0W cells was loaded into each lane.
Electrophoresis was performed in TAE buffer (40 mM Tris-
acetate. 1 mM EDTA) for 5 h at 2 V cm DNA was stained
using SYBR Green II dye (Molecular Probes, Eugene. OR.
USA). As molecular weight marker, a 123 bp DNA ladder
(Gibco, Paisley, UK) was co-migrated. Gels were photo-
graphed under UV light (254 nm epi-illumination) with
Polaroid type 667 film using a SYBR Green filter (Molecular
Probes).
Quantification ofthe apoptotic cellfraction
Cells (2 x 106 cells per well) were exposed to various concen-
trations (0-400 JAM) of ara-C or NHAC for 24 h at 37TC (5%
carbon dioxide) or for various time periods (0-24 h) with
50gAM ara-C or NHAC. After the incubation, the cells were
prefixed in suspension on ice for 15min in HBSS (pH 7.4)
containing 1% formaldehyde. Then the cells were centri-
fuged. washed once in cold HBSS and resuspended in 500Jl
HBSS. The cells were then injected through a fine needle into
4.5 ml 80% ethanol (precooled to - 2OC) for post-fixation
and stored at - 2OC for up to 3 days. The staining pro-
cedure was performed with minor modifications as described
by Hotz et al. (1994). Briefly, after rehydrating the cells in
HBSS. they were resuspended in 50 iLl buffer containing 0.2 M
potassium cacodylate, 2.5 mM Tris-HCI (pH 7.0), 2.5 mM
cobalt chloride, 0.25 mg ml-' BSA, 7 units of TdT and
0.5 nmol b-dUTP. After 30 min incubation at 37C, the cells
were washed once in HBSS and resuspended in 100gl of a
solution containing 4 x saline citrate buffer (0.6M sodium
chloride, 0.06 M trisodium citrate), 10% non-fat dry milk and
2.5 gig ml - fluoresceinated avidin. The cells were incubated
for 30 min in the dark, washed once with HBSS and
resuspended in Iml HBSS+PI (5igmVml)+0.lI% RNAse
A.
Flow cytometrY and data analysis
All cell preparations were analysed with a FACStar Plus
instrument (Becton-Dickinson, San Jose. CA, USA) inter-
faced with a Hewlett Packard computer. A single 5 W argon-
ion laser beam (488 nm) running at 100 mW was used to
simultaneously excite the fluorescein and PI dyes. Green
fluorescence was collected through a 530 nm-band pass filter
and red fluorescence through a 575 nm band pass filter.
Single stained samples (fluorescein or PI dye) were used to
optimise instrument settings and ensure proper electronic
compensation. Each analysis was carried out on 10 000 cells
at a rate of about 500 cells sl'. Doublets were eliminated by
gating bivariate histograms on the DNA fluorescence peak Vs
area cytograms. Data were stored in list mode and analysed
using Lysys II and PC-Lysys software (Becton-Dickinson,
San Jose. CA, USA).
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Results
Clonogenic assay
Figure 1 shows the results of the clonogenic assays of
liposomal NHAC and ara-C in HL-60 cells and HL-60 ara-
C-resistant cells respectively. It should be noted that a direct
comparison of the HL-60 and HL-60 ara-C cell lines is
difficult to make owing to their different growth characteris-
tics. The doubling time was found to be 30 h for the HL-60
cells and 22 h for the HL-60 ara-C cells. Empty liposomes
were not toxic in both cell lines at lipid concentrations
ranging up to 1.6 mg ml-' SPC corresponding to a concen-
tration of 400 J.M NHAC in the drug containing liposomes.
In HL-60 cells (Figure la) ara-C was more effective in
growth inhibition than NHAC. resulting in an IC50 value of
1.0 ± 0.1 Am compared with 2.9 ± 0.3 gM for NHAC. In HL-
60/ara-C cells, however, NHAC was significantly more
effective than ara-C. The IC50 values are 30.4 ± 0.9 gm for
ara-C and 1.3 ± 0.1 lm for NHAC respectively. These results
indicate that NHAC is able to overcome ara-C resistance in
the HL-60 ara-C cell line not only in short-time cytotoxicity
assays (MTT test). as reported previously (Horber et al.,
1995a). but also in clonogenic growth inhibition assays over
14-21 days after 24h drug exposure.
Cell cycle distribution anal vsis
The changes in the cell cycle distribution of HL-60 and
HL-60 ara-C cells after 24 h incubation with increasing con-
centrations of ara-C or NHAC are summarised in Table I.
Empty liposomes led to no changes in the cell cycle distribu-
tion after a continuous 24 h incubation (data not shown).
Whereas ara-C led to the typical reduction of S-phase cells
even at 1 gM drug concentration. NHAC up to 40 JM
showed no significant reduction in S-phase cells. As
previously reported, small amounts of NHAC can be cleaved
in HL-60 cells to ara-C. which in turn is phosphorylated to
ara-CTP (Horber et al.. 1995a). This effect might explain the
reduction in S-phase cells at higher NHAC concentrations in
HL-60 cells. but not in HL-60 ara-C resistant cells.
Basically. the reduction in S-phase cells can be explained
by the DNA polymerase inhibition of ara-CTP, which
prevents the incorporation of BrdUrd. Thus, after incubation
with ara-C or high concentrations of NHAC. early S-phase
cells are found after DNA polymerase inhibition in the GI
phase population. middle S-phase cells in the S0 phase
population and finally late S-phase cells in the G,2M phase
population (see also Figure 2). Each reduction in S-phase
HL-60 cells was therefore followed by an increase in GI, SO
and G, M phase cells (Table 1). SO phase cells are cells which,
due to their DNA content belong to the middle S-phase cell
fraction, but they do not incorporate BrdUrd into the DNA
DNA because of the DNA polymerase inhibition of ara-C
(Preisler et al.. 1992).
In Figure 2 the typical cell, cycle distribution patterns in
HL-60 cells are shown for untreated cells and cells treated
with 40 #M ara-C or NHAC. SO phase cells are located
between the G1 and G. M phase cell fraction. Taking into
account that the ICo value of NHAC in the MTT cytotoxi-
city test was found to be 47 tLM (Horber et al., 1995a) and
that the cell cycle distribution after treatment with NHAC is
not markedly changed up to 40 tLM (Table I), the mechanisms
of cytotoxicity of NHAC have to be considered as phase
unspecific. At higher drug concentrations, however, a more
pronounced effect caused by ara-C formed from metabolised
NHAC leads to a specific S-phase cytotoxicity in HL-60 cells.
In the resistant HL-60 ara-C cells ara-C exerted its S-
phase-specific toxicity only above 100 gM. At lower drug
concentrations, the S-phase cell fraction even increased from
56% to 70% due to a shift of GI phase cells to early S-phase
cells (data not shown). NHAC again revealed no phase-
specific cytotoxicity at lower drug concentrations, whereas
the toxicity at drug concentrations above 100 ILM was S-phase
specific. but less pronounced as in the sensitive HL-60 cell
line.
The results of the time-dependent cell cycle distribution
assays are shown in Table II. Ara-C exerted its S-phase-
specific cytotoxicity within the first 2 h of incubation.
Likewise, in the HL-60 ara-C-resistant cells. ara-C induced
first a slight decrease of the S-phase cell fraction, but after
8 h the phase distribution changed because of a significant
increase of early S-phase cells (data not shown). NHAC on
the other hand exerted no significant effects on the cell cycle
distribution in HL-60 and HL-60 ara-C cells at 50 gM drug
concentration.
Quantification of the apoptotic cellfraction
The induction of apoptosis in HL-60 and HL-60 ara-C cells
after incubation with increasing concentrations of ara-C or
NHAC is summarised in Table III. In contrast to NHAC.
ara-C induced apoptosis in a significant fraction of HL-60
cells already at 1 ylM drug concentration, but it was not able
to increase the fraction of apoptotic cells to more than 28%
during 24 h incubation. This cell population might be
represented by the S-phase cell fraction, which was shown to
disappear during incubation even with 1 liM ara-C (Table I).
The well-known property of ara-C to block GI phase cells at
the GI/S border hinders or delays therefore the induction of
apoptosis in more cells. NHAC on the other hand, was able
to induce apoptosis only at concentrations higher than
20 gM. Compared with ara-C, however, NHAC induced
apoptosis in more than 50% of the cells at concentrations of
200 JiM and higher, indicating that the induction of apoptosis
might not be limited to S-phase cells. Figure 3 illustrates the
Table II Cell cvcle distribution in HL-60 and HL-60 ara-C cells after incubation with 50 LM
ara-C or NHAC for various incubation timesa
Tim Time
thy
Ara-C
0
4
8
24
Distribution in HL-60 cells (%O
GI s oSb G.U
57.8b
71.8
81.2
83.1
77.5
33.5
6.4
4.7
4.4
3.8
1.0
10.3
6.1
4.0
6.8
7.7
11.5
7.9
8.5
11.9
Distribution in HL-60 ara-C (%0)
GI S S(o G. M
36.3
44.8
52.6
52.4
28.2
53.5
47.2
39.9
37.8
62.3
1.1
1.4
1.7
4.3
2.1
9.2
6.7
5.8
5.4
7.4
NHAC
0 56.9 34.3 1.1 7.7 36.8 52.3 1.2 9.6
55.1 38.0 1.2 5.7 37.1 55.1 1.3 6.6
4 59.5 33.5 2.1 4.9 33.4 57.8 1.0 7.7
8 59.6 35.1 2.0 3.3 37.2 51.9 1.1 9.8
24 56.7 31.9 3.0 8.4 34.1 50.5 1.2 14.2
'Cell cycle distribution determined using the BrdUrd-PI method. 'SO cel fraction as
described in the text. CMean of cell cycle fractions (%) of two separate expenrments. s.d. was
always <10% of mean value.
1070Table m Induction of apoptosis by ara-C or NHAC in HL-60 and
HL-60/ara-C cells after 24 h incubation with increasing drug
concentrationsa
Drug concentration HL-60 cells HL-601ara-C cells
(JAM) Ara-C NHAC Ara-C NHAC
0 1.9±0.4b 1.6±0.9 2.3±0.2 2.4±0.1
1 17.4± 1.6 2.1 0.0 2.2±0.2 2.7±0.1
10 22.5±0.3 1.6 1.2 2.8±0.1 3.0±0.1
20 22.8 2.1 4.3 1.1 3.0 0.0 3.4 0.2
40 27.7 2.1 7.4 0.7 4.4 0.9 4.2 0.2
60 27.3 ± 2.8 20.6 ± 2.2 4.7 ± 0.2 5.3 ± 0.7
100 25.2 0.2 37.2 0.1 4.8 0.6 9.8 0.2
200 23.9 ± 5.2 51.8 ± 0.7 4.9 ± 0.2 21.8 ± 3.6
400 17.3 ± 0.1 61.3 ± 1.9 7.9 ± 0.2 45.2 ± 3.3
'HLb60 and HL-60/ara-C cells were incubated for 24 h with
increasing concentrations of ara-C or NHAC. Apoptotic cell
fractions were determined by flow cytometry using the TdT-PI
method. bMean of apoptotic cell fractions ± s.d. (%) from two
separate experiments.
determination of apoptotic cell fractions by flow cytometry
analysis in untreated HL-60 cells and in HL-60 cells after
incubation with 20 AM ara-C or NHAC.
The fraction of HL-60/ara-C cells undergoing apoptosis
after treatment with ara-C was significantly smaller as com-
pared with the sensitive cells. Compared with ara-C, NHAC
induced apoptosis in more HL-60/ara-C cells, however,
higher drug concentrations compared with the sensitive HL-
60 cell line were required (Table III). This finding would
indicate that either the sensitivity for induction of apoptosis
in the HL-60/ara-C cell line is lower or that there might exist
a synergistic effect between the yet unknown mechanisms of
cytotoxicity of NHAC and the ara-C orginating from
NHAC.
The time-dependent induction of apoptosis in HL-60 and
HL-60/ara-C cells is summarised in Table IV and illustrated
by agarose gel electrophoresis in Figure 4. Apoptosis occur-
red in HL-60 cells between 2 and 4 h incubation after treat-
ment with ara-C and NHAC. These findings were confirmed
by agarose gel electrophoresis. As listed im Table IV, the cell
fractions undergoing apoptosis in the HL-60/ara-C cell line
were small. Therefore, the DNA ladder pattern was not
visible on agarose gels (data not shown). The occurrence of
apoptotic cells after NHAC incubation was again detected
after 2-4 h incubation, whereas the increase in the apoptotic
cell fraction after ara-C treatment was not significant during
24 h incubation.
Previous investigations gave evidence that NHAC exerts
cytotoxic mechanisms which are significantly different from
those of ara-C. Therefore, to elucidate further these
mechanisms of action we studied in the present work the
clonogenic toxicity of a liposomal formulation of NHAC, its
influence on the cell cycle distnrbution and its ability to
induce apoptosis in ara-C-sensitive and resistant HL-60 cells.
Since NHAC was found to exert strong cytotoxic activity in
a short-time exposure assay (MTT test) (Horber et al., 1995a)
it was first investigated if NHAC could also preserve its
cytotoxicity in a long-time clonogenic growth inhibition assay
lasting 14-21 days after a 24 h drug exposure. Compared
with the MIT test, the clonogenic assays were significantly
more sensitive with both cell lines. In particular, ara-C had
greater effects on clonogenic growth inhibition than on short-
time cytotoxicity. NHAC, on the other hand, was superior to
ara-C in the HL-60/ara-C cell line, indicating that this drug is
able to overcome ara-C resistance even in a clonogenic
growth inhibition assay. It should be emphasised, however,
that the results of the studies on cell cycle distribution and
induction of apoptosis have to be interpreted in the context
of the short-time exposure cytotoxicity assay (Horber et al.,
1995a), rather than the clonogenic growth inhibition assay.
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Frge 3 Detection of apoptosis-associated DNA strand breaks
using the in situ TdT assay. Untreated HL-60 cells (a) or cells
exposed to 20jaM ara-C (b) or NHAC (c) for 24 h at 3TC (5%
carbon dioxide) were fixed and incubated in the presence of
exogenous TdT and b-dUTP. Staining was performed using
FITC-labelled avidin and PI. Data are shown as contour plots
with DNA content on the x-axis (FL-2, red fluorescence) and
b-dUTP incorporation on the y-axis (FL-1, green fluorescence).
The apoptotic cell fraction was quantified by gating. All
experiments were performed in duplicate.
The influence of liposomal NHAC on the cell cycle distri-
bution of HL-60 cells revealed that NHAC exerts its
mechanisms ofcytotoxicity at lower concentrations mainly in
a phase-unspecific manner, whereas at higher concentrations
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Table IV Induction of apoptosis by 50piM ara-C or NHAC in
HL-60 and HL-60/ara-C cells after various incubation timesa
Incubation tine HL-60 cells HL-60/ara-C cells
(h) Ara-C NHAC Ara-C NHAC
0 1.6 0.3b 1.9 0.2 1.1 0.2 1.1 ± 0.3
2 2.2±0.3 2.2±0.4 1.6±0.2 0.9±0.1
4 17.7±0.2 4.8±0.4 1.6±0.2 3.4±0.5
6 21.0 1.1 5.7±0.3 1.3±0.1 4.9±3.3
8 20.6 0.3 7.6 0.5 1.4 0.1 5.4 0.9
24 25.2 ± 2.8 10.4 1.2 2.4 ± 0.9 5.5 ± 0.2
'HL-60 and HL-60/ara- cells were incubated for 0-24h with
50I1M ara-C or NHAC. Apoptotic cell fraction was determined by
flow cytometry using the TdT-PI method. bMean of apoptotic cell
fraciuons ± s.d. (%) from two separate experiments.
Fwe 4 Agarose gel eletrophoresis for the detection of
endonuceolytic DNA fragmentation in HL-60 cells inducd by
incubation with 50ILM ara-C (Lanes 2-6) or NHAC (Lanes
7-11) for various time periods ranging from 0-8 h. As marker a
123 bp ladder was used (Lanes I and 12).
an increasing ara-C effect, resulting from small concentra-
tions of NHAC metabolised to ara-C and ara-CTP, leads to
a specific S-phase toxicity in HL-60 cells. In the resistant
HL-60/ara-C cells, NHAC similarly exerted a phase-
unspecific toxicity at lower concentrations ranging up to
100 JM, whereas higher drug concentrations led to an in-
creased S-phase toxicity. However, this specific toxicity can-
not be explained by ara-C effects originating from NHAC
due to the pronounced ara-C resistance of the HL-60/ara-C
cell line. Therefore, NHAC itself or one of its yet unklnown
metabolites have to be considered as S-phase-specific at high
drug concentrations.
The tirm-dependent studies revealed that the S-phase
specific inhibition of DNA synthesis occurs within the first
two incubation hours. The results from these studies indicate
that NHAC exerts its cytotoxicity at lower concentrations
not by inhibition of DNA synthesis or DNA polymerase aE,
because both mechanisms would lead to specific S-phase
toxicity, whereas at high concentrations NHAC might be
active in an S-phase-specific manner. For an improved detec-
tion of the apoptotic DNA ladder by agarose gel elect-
rophoresis, SYBR Green II was used for staining instead of
ethidium bromide. This new fluorescent stain gave better
results in the depiction of the ladder pattern and was more
sensitive in detecting single-strand DNA, which might occur
in apoptotic cells (Bertrand et al., 1991; Yoshida et al., 1993).
As reported by Gorczyca et al. (1993b), necrotic cells can
not be labelled with b-dUTP, because either the number of
DNA strand breaks is low or the 3'-OH termini in these
breaks are not accessible to TdT, in contrast to cells under-
going apoptosis. Therefore, the fraction of cells undergoing
necrosis cannot be determined using this method, because
they cannot be separated from the normal cell population. In
addition, the apoptotic cell fractions do not contain any
necrotic cells. The determination of apoptotic cell fractions in
HL-60 and HL-60/ara-C cells revealed that ara-C is able to
induce this mechanism of cell death at much lower concen-
trations than NHAC, but only to a limited fraction of cells,
which represents the S-phase cells, whereas the induction of
apoptosis by NHAC is suggested not to be limited to S-phase
cells (Tables I and HI). This limitation of ara-C toxicity to
S-phase cells, together with its rapid inactivation, makes it
necessary to administer this drug in vivo either continuously
for 5 days (Frei et al., 1969) or at high-dose regimens up to
3 gm-2 (Momparler, 1974). As demonstrated with incuba-
tions with high NHAC concentrations in both cell lines, the
large number of cells undergoing apoptosis does not only
depend on the formation of ara-CTP formed from NHAC.
These small amounts of ara-C formed from NHAC are
unlikely to induce apoptosis in HL-60/ara-C cells, as shown
by the direct incubation with ara-C (Table III). NHAC itself
(or one of its yet unklnown metabolites, with the exception of
ara-C) at concentrations > 200 gM is able to induce apop-
tosis even in HL-60/ara-C-resistant cells.
The comparison of the time-dependent studies of apoptosis
induction with the cell cycle distribution clearly shows that
the inhibition of DNA synthesis in HL-60 cells occurs within
the first 2 h of incubation with ara-C, whereas apoptotic cells
appear only after longer lasting drug exposure (Table I). In
HL-60/ara-C cells, NHAC also induced apoptosis 4-24h
after the beginning of incubation, however, at fractions not
reaching more than 5.5% of the cell population. Ara-CTP
formed from NHAC is unlikely to be responsible for the
DNA fragmentation, as shown by direct incubation with
ara-C.
In conclusion, our study gives further evidence that NHAC
has significntly different cytotoxic mechanisms than ara-C
and that this hpophihic derivative is able to overcome ara-C
resistance Thus, NHAC exerts at concentrations of 1-40 gM
a phase-independent cytotoxicity and is able to induce apop-
tosis at higher concentrations, which is not restricted to
S-phase cells. Together with its highly improved stability
against deamination, these properties might explain why
NHAC can be administered at lower doses and with single-
dose schedules to obtain even better anti-tumour effects than
ara-C in the murine L1210 leukaemia model (Schwendener
and Schott, 1992).
The exact mechanism of action of NHAC, however, is not
yet elucidated and further studies are required. One possible
mechanism of action for NHAC, fitting into the findings
described here, may consist in an interference of NHAC with
signal transduction pathways, which was also described as a
mechanism for synthetic anti-tumour alkyl ether lipids (Berg-
gren et al., 1993; Lohmeyer and Workman, 1993; Lohmeyer
and Bittman, 1994; Houlihan et al., 1995). Therefore, further
investigations with NHAC will be necessary to clarify its
effects on intracellular cell signalling. The chemical structure
of NHAC with its highly lipophilic alkyl moiety and the
ara-C component may also raise the assumption that its
cytotoxic action consists in a combination of mechanisms
such as those of the ether lipids and, at a reduced rate, those
of ara-C.
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